Innovation in Pediatric Drugs Act of 2024

The Innovation in Pediatric Drugs Act of 2024 updates FDA requirements for pediatric drug studies, primarily affecting pharmaceutical companies developing drugs for children. It requires the FDA to issue a noncompliance letter and allow a 45-day response period before taking enforcement action for missed pediatric study deadlines, and mandates the FDA to maintain an online list of diseases where pediatric studies are automatically waived. The bill specifically addresses orphan drugs (for rare diseases) by clarifying when pediatric studies apply and requiring new FDA guidance on their development. These changes aim to balance regulatory compliance with practical challenges in developing pediatric treatments for rare conditions.